BIND Therapeutics (BIND) To Present Data At The 26th EORTC-NCI-AACR Symposium
8/26/2014 10:23:13 AM
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that a poster presentation including Phase 2 clinical data on its lead drug candidate, BIND-014, in patients with non-small cell lung cancer (NSCLC) will be presented at the upcoming 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The meeting, which is hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), takes place November 18-21, 2014, in Barcelona, Spain.
Help employers find you! Check out all the jobs and post your resume.
comments powered by